TY - JOUR
T1 - Management of atherogenic dyslipidemia of the metabolic syndrome
T2 - Evolving rationale for combined drug therapy
AU - Vega, Gloria Lena
PY - 2004/9
Y1 - 2004/9
N2 - Atherogenic dyslipidemia is common in a variety of conditions associated with central obesity, hypertension, hyperurecemia, and impaired pancreatic β cell function, (ie, the metabolic syndrome). Most high-risk patients who have atherogenic dyslipidemia will require statin therapy; such therapy is encouraged on the basis of clinical trial evidence. Coadministration of drugs targeted for the reduction of LDL precursors (VLDL and IDL) are likely to improve the profile of atherogenic lipoproteins. In addition, coadministration will produce a significant rise in HDL cholesterol. Large clinical trials that show CHD risk reduction or improvement in CHD are needed with combined drug therapy. New drugs undoubtedly are needed to target fatty acid metabolism and inflammation. As we progress in the understanding of the metabolic origins of atherogenic dyslipidemia, new targets of therapy likely will be identified and new drug combinations will prove to be even more efficacious than those currently available for treatment of atherogenic dyslipidemia.
AB - Atherogenic dyslipidemia is common in a variety of conditions associated with central obesity, hypertension, hyperurecemia, and impaired pancreatic β cell function, (ie, the metabolic syndrome). Most high-risk patients who have atherogenic dyslipidemia will require statin therapy; such therapy is encouraged on the basis of clinical trial evidence. Coadministration of drugs targeted for the reduction of LDL precursors (VLDL and IDL) are likely to improve the profile of atherogenic lipoproteins. In addition, coadministration will produce a significant rise in HDL cholesterol. Large clinical trials that show CHD risk reduction or improvement in CHD are needed with combined drug therapy. New drugs undoubtedly are needed to target fatty acid metabolism and inflammation. As we progress in the understanding of the metabolic origins of atherogenic dyslipidemia, new targets of therapy likely will be identified and new drug combinations will prove to be even more efficacious than those currently available for treatment of atherogenic dyslipidemia.
UR - http://www.scopus.com/inward/record.url?scp=3242664106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3242664106&partnerID=8YFLogxK
U2 - 10.1016/j.ecl.2004.03.013
DO - 10.1016/j.ecl.2004.03.013
M3 - Review article
C2 - 15262295
AN - SCOPUS:3242664106
SN - 0889-8529
VL - 33
SP - 525
EP - 544
JO - Endocrinology and Metabolism Clinics of North America
JF - Endocrinology and Metabolism Clinics of North America
IS - 3
ER -